Discover open access scientific publications

Search, annotate, share and cite publications

Publications by V. REPISKA

Molecular Analysis of EGFR Gene in Different Types of Tumor Material From NSCLC Patients

Neoplasma

Cancer Research

2015

English

Related publications

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology

English

MA15.07 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

Journal of Thoracic Oncology

English

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

Journal of Thoracic Oncology

English

MA25.11 Clinical and Molecular Predictors of Outcome in Patients With EGFR Mutant NSCLC Brain Metastases Treated With RT

Journal of Thoracic Oncology

English

MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis

Journal of Thoracic Oncology

English

P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.

Journal of Thoracic Oncology

English

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Biologics: Targets and Therapy

English

Bisphosphonates Enhance Antitumor Effect of EGFR-TKIs in Patients With Advanced EGFR Mutant NSCLC and Bone Metastases

Scientific Reports

Multidisciplinary

2017

English

P2.13-26 Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated With First-Line TKI

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by V. REPISKA

Molecular Analysis of EGFR Gene in Different Types of Tumor Material From NSCLC Patients

Related publications

JCSE01.21 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

MA15.07 Different Responses to Osimertinib in Primary and Acquired EGFR T790m-Mutant NSCLC Patients

MA15.09 Dynamic Monitoring and Predictive Value of Circulating Tumor Cells in EGFR Mutant Advanced NSCLC Patients Treated With First-Line EGFR-TKIs

MA25.11 Clinical and Molecular Predictors of Outcome in Patients With EGFR Mutant NSCLC Brain Metastases Treated With RT

MA08.03 EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR Mutated NSCLC Patients With Brain Metastases: A Meta-Analysis

P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Bisphosphonates Enhance Antitumor Effect of EGFR-TKIs in Patients With Advanced EGFR Mutant NSCLC and Bone Metastases

P2.13-26 Impact of Concurrent Tumor Suppressor Gene Mutation on Clinical Outcomes in EGFR Mutated NSCLC Treated With First-Line TKI